Cytiva opens Cell Culture Center of Excellence in Massachusetts

Cytiva opens Cell Culture Center of Excellence in Massachusetts 

• Strengthens Cytiva’s cell culture services to transform the future of process development
• 11 500 sq ft facility close to Boston’s biotech hub
• Combination of scientific expertise and latest technology helps customers reduce development timelines, improve process performance, and increase speed to market

November 9, 2022

Global life sciences leader Cytiva opened a new Cell Culture Center of Excellence at its Marlborough, Massachusetts location. The center is part of the company’s long term growth strategy, providing expanded cell culture media development capabilities and new cell line development services. Cytiva now provides a comprehensive approach to supporting customers working in early process development.

Amanda Halford, Vice President, BioProcess, Cytiva, says: “Our Cell Culture Center of Excellence combines our scientific expertise with the latest technology. Our tailored solutions enable customers to bring a wide range of molecules from discovery to delivery – smarter and faster.”

Developing a cell line is a critical first step in the life cycle of a therapeutic. It can involve considerable time and resources – both potentially limiting for the bioprocess industry. Collaborating with an industry expert like Cytiva to develop tailored solutions for cell culture media and cell line development can reduce customer development timelines, improve process performance, and increase speed to market.

The new 11 500 ft² facility is close to the Boston biotech hub and the breadth of scientific talent the area has to offer. The center will be run by experienced scientific teams and staff dedicated to transforming the future of process development.

About Cytiva

At Cytiva, we believe the key to transforming human health is accessing life-changing therapies. That’s why our nearly 10 000 associates in more than 40 countries are keenly focused on helping researchers, biopharma companies, and drug manufacturers to advance and accelerate therapeutics for people that need them. We’re driven by their desire to achieve better flexibility, capacity, and efficiency in all facets of their work – all the way from discovery to delivery.